TrialThe Lancet. Respiratory medicine2022

Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial.

Holly R Keir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.